Abstract: SA-PO1234
Effect of GFR Difference on the Overall Survival of Adult Patients Exposed to Anticancer Treatment
Session Information
- Onconephrology: Epidemiological Trends, Risk Stratification, and Clinical Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1600 Onconephrology
Authors
- Caires, Renato A., Universidade de Sao Paulo, São Paulo, SP, Brazil
- Inker, Lesley, Tufts Medical Center, Boston, Massachusetts, United States
- Allam, Krishna C., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
- Burdmann, Emmanuel A., Universidade de Sao Paulo, São Paulo, SP, Brazil
- Costa e Silva, Veronica Torres, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background
Relative difference between the eGFR calculated using serum cystatin C (Scys) (eGFRcys) and creatinine (Scr) (eGFRcr) is associated with higher mortality in the overall population. Cancer patients have a higher proportion affecting non-GFR determinants of both Scr and Scys. We aim to evaluate the impact of eGFR difference (eGFRdiff) on overall survival (OS) in patients exposed to anticancer treatment
Methods
This is a prospective cohort of adult patients with solid tumors exposed to anticancer treatment at a Brazilian tertiary cancer center. eGFRcr and eGFRcys were calculated using race-free CKD-EPI equations at treatment initiation (T0) and at treatment completion (TF). Scr and Scys were measured through certified reference materials at the University of Minnesota. eGFRdiff was calculated as (eGFRcys-eGFRcr)/eGFRcr x100%
Results
A cohort of 485 patients was recruited between Oct 2017 and Jan 2019. Patients were 53±15y old, 62% female, and 93% with ECOG score 0/1. The most frequent cancer sites were breast (31%) and gastrointestinal (31%);41% had metastasis at diagnosis. The most frequently prescribed drugs were platinum compounds (cisplatin, carboplatin, oxaliplatin) (53.7%) and paclitaxel (39.8%). Patients received a median of 4 (3-6) cycles over 105 (63-148) days of therapy. T0 was collected at 4 (1-7) days before treatment initiation, and TF was collected 124 (44-204) days after therapy was concluded. The follow-up period was 28 (21-32) months; mortality was 30.5%. In the adjusted Cox regression model, eGFRdiff at T0 was not associated with OS. At TF, eGFRdiff above 10% and 20% were predictors of increased OS, whereas eGFRdiff below -20% was a predictor of reduced OS (Table)
Conclusion
In this cohort of adult patients with solid tumors undergoing anticancer therapy, eGFRdiff after treatment was associated with long-term survival and could be used as a prognostic tool in patients with cancer